期刊文献+

2型糖尿病患者护骨素与内皮依赖性血管舒张功能的关系 被引量:3

Relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetic patients
原文传递
导出
摘要 目的探讨2型糖尿病患者护骨素与内皮依赖性血管舒张功能(EDAD)的关系。方法选择40例新诊断的2型糖尿病患者和46名健康个体。2型糖尿病患者采用胰岛素治疗6个月。血浆护骨素采用ELISA法测定。采用高分辨血管外超声法检测肱动脉血流介导的EDAD和硝酸甘油介导的内皮非依赖性血管舒张功能。结果2型糖尿病患者治疗前血浆护骨素为(3.44±0.52)ng/L,明显高于对照组(2.38±0.25)ng/L(P<0.01),治疗6个月后血浆护骨素水平明显降低(2.61±0.55)ng/L(P<0.01)。2型糖尿病患者治疗前EDAD为(3.19±0.52)%,明显低于对照组的(4.46±0.56)%(P<0.01),治疗6个月后明显改善(4.18±0.48)%(P<0.01)。多元相关分析显示,治疗前血浆护骨素与EDAD、空腹血糖(FPG)、HbA_(IC)、超敏C反应蛋白(CRP)相关(均P<0.01)。治疗前后护骨素的变化与EDAD、FPG、HbA_(IC) CRP的变化相关(P<0.01)。结论新诊断的2型糖尿病患者血浆护骨素水平明显增高,血浆护骨素与血管内皮功能相关。 Objective To research the relationship between plasma osteoprotegerin (OPG) level and endothelium-dependent arterial dilation (EDAD) in type 2 diabetic patients. Methods The subjects included 40 newly diagnosed type 2 diabetic patients and 46 healthy subjects. Insulin therapy were then given to all diabetic patients for 6 months. Plasma OPG was measured by a sandwich ELISA method, and brachial artery diameter was determined by high resolution ultrasound at rest after reactive hyperemia and after sublingual glyceryl trinitrate (GTN). Results Plasma OPG level in diabetic patients before treatment was (3.44 ± 0.52)ng/L, which was significantly higher than that in control (2.38 ± 0.25 )ng/L (P 〈 0.01 ), and was decreased markedly after 6- month treatment (2.61 ±0.55) ng/L (P 〈0.01 ). EDAD in patients before treatment was (3.19 ±0.52)%, which was significantly lower than that in control (4.46 ± 0.56 ) % ( P 〈 0.01 ), and improved markedly after 6 months treatment (4.18 ± 0.48 )% (P 〈 0.01 ). In multivariate analysis, OPG was significantly associated with EDAD, fasting plasma glucose (FPG), HbA,c and ultra sensitive C-reactive protein (CRP) at baseline (all P 〈 0.01 ). The absolute change in OPG showed significant correlation with the changes in EDAD, FPG, HbA,c, and CRP in diabetic patients during the course of treatment ( all P 〈 0.01 ). Conclusion Plasma OPG level is elevated in newly diagnosed diabetic patients and is significantly associated with vascular endothelial function.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2007年第3期231-234,共4页 Chinese Journal of Endocrinology and Metabolism
关键词 护骨素 血管内皮功能 糖尿病 2型 Osteoprotegerin Vascular endothelial dysfunction Diabetes mellitus, type 2
  • 相关文献

参考文献20

  • 1Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89 : 309 -319.
  • 2Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vas Biol, 2001,21:1998-2003.
  • 3Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS letters, 2002,521 : 180-184.
  • 4Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 2002,106 : 1192-1194.
  • 5Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease, J Clin Endocrinol Metab, 2003,88 : 1024-1028.
  • 6Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol, 2003,149:39-42.
  • 7Avignon A, Sultan A, Piot C, et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients, Diabetes Care, 2005,28:2176-2180.
  • 8Browner WS, Lui LY, Cummings SR, Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fracture, and mortality in elderly women, J Clin Endocrinol Metab, 2001,86 : 631- 637.
  • 9Boneti PO, Lerman LO, Lerman A. Endothelial dysfunction, a marker of atherosclerotic risk. Arterioscler Thromb Vas Biol, 2003,23 : 168- 175.
  • 10向光大,何玉生,蒋文,胡泰洪.女性2型糖尿病患者载脂蛋白e4等位基因与内皮依赖性血管舒张功能降低有关[J].中华内分泌代谢杂志,2005,21(1):9-12. 被引量:9

二级参考文献20

  • 1冯波,李栩,黄亦文,乐秀康,富明,陈明慧,戴明德,倪亚芳,赵竹芳,周凤英,孟仲莹,王惠玲,姚国良,张容,刘昊,张小倩.上海市浦东新区社区人群代谢综合征状况和相关危险因素分析[J].中华内分泌代谢杂志,2004,20(3):231-232. 被引量:34
  • 2向光大,何玉生,蒋文,胡泰洪.女性2型糖尿病患者载脂蛋白e4等位基因与内皮依赖性血管舒张功能降低有关[J].中华内分泌代谢杂志,2005,21(1):9-12. 被引量:9
  • 3向光大,杨香玖,丁晓华,伍欣星,徐焱成.NIDDM患者不同血管并发症ApoE基因型频率分布的研究[J].中华医学遗传学杂志,1995,12(4):197-200. 被引量:15
  • 4Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis, 1998,8:1-21.
  • 5Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a′thrifty′ allele? Ann Hum Genet, 1999,63(Pt 4):301-310.
  • 6Wang XL, McCredie RM, Wilcken DE. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol, 1995,15:1030-1034.
  • 7Katzel LI, Fleg JL, Paidi M, et al. ApoE4 polymorphism increases the risk for exercise-induced silent myocardial ischemia in older men. Arterioscler Thromb, 1993,13:1495-1500.
  • 8Guangda X, Banshun X, Xiujian L, et al. Apo varepsilon (4) allele increases the risk for exercise-induced silent myocardial ischemia in non-insulin-dependent diabetes mellitus. Atherosclerosis, 1999,147:293-296.
  • 9Guangda X, Yuhua W. Apolipoprotein e4 allele and endothelium-dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia, 2003,46:514-519.
  • 10Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med, 1986,314:488-500.

共引文献17

同被引文献34

  • 1高彦宇,葛鹏玲,李冀.降脂饮对胰岛素抵抗大鼠血脂的早期干预[J].中医药学报,2009,37(4):24-26. 被引量:1
  • 2李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 3余臣祖,张朝宁,刘国安.实验性2型糖尿病动物模型研究进展[J].医学综述,2006,12(1):41-42. 被引量:33
  • 4Ruiz-Torres A, Lozano R, Melon J, et al.On how insulin may fluence ageing and become atherogenic throughout the insulin-like growth factor-1 receptor pathway: invitro studies with human vascular smooth muscle cetls[J].Gerontology,2005,51 (4) :225.
  • 5Ping O,Kirsten N,Lise W, et al. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin [J]. Am J Physiol Heart Circ Physiol, 2007,292 ( 2 ) : H 1058.
  • 6Fiorella G, Stefano S, Roberto S, et al. Osteoprotegerin serum levels in children with type 1 diabetes: A potential modulating role in bone status [J]. Eur J Endocrinol, 2005,153 (6) :879.
  • 7Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 Diabetic patients with microvascular complications [J] Eur J Endocrinol,2003.149 (2) 39.
  • 8Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary-artery disease[J]. Circulation ,2002,106(10) : 1192.
  • 9Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mor- tality in elderly women[J]. J Clin Endocrinol Metab, 2001,86(2): 631.
  • 10Jang YS, Young GS, Choon HC. Elevated serum osteoprotegerin levels are Associated with vascular endothelial dysfunction in type 2 diabetes [J].Diabetes Care, 2006, 29(7) : 1664.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部